Molecular targeting on oncogene is a new therapeutic modality now under intense investigation. Recent clinical success of human epidermal growth factor receptor 2 (HER2) inhibitors in treating metastatic gastric cancers ([@bib2]) have raised hopes that the identification of other deregulated oncogenic pathways in gastric cancer will lead to new therapeutic options for gastric cancer. MET, the hepatocyte growth factor receptor, is another receptor tyrosine kinase overexpressed and activated in a subset of human epithelial malignancy. An activated MET signalling pathway via gain-of-function mutation or amplification of the *MET* gene promotes tumour cell growth, survival, migration, and invasion as well as tumour angiogenesis ([@bib19]). *MET* gene mutation has been found mainly in hereditary papillary renal cell carcinoma ([@bib27]) and in a subset of lung cancer ([@bib20]). Previous studies described *MET* gene amplification (GA) in 4% of non-small-cell lung cancers ([@bib3]; [@bib9]), in 4% of oesophageal cancer ([@bib21]), and in endometrial cancer ([@bib26]). In gastric cancer, it has been reported that *MET* amplification was found in 0--23% of gastric cancers, and MET overexpression and/or GA was associated with advanced disease stage and/or worse clinical outcome ([@bib11]; [@bib22]; [@bib12]; [@bib1]; [@bib10]; [@bib14]; [@bib17]; [@bib18]; [@bib33]; [@bib29]). However, most studies were limited by small cohort sizes, and there were few studies performed in a large, unselected, consecutively accrued gastric cancer cohort.

Based on the strong association of abnormal MET signalling with human cancers, tyrosine kinase inhibitors and therapeutic monoclonal antibodies that antagonise MET activation have been actively developed ([@bib19]). Furthermore, preclinical findings indicate that MET pathway may represent a therapeutic target for gastric carcinoma by showing that gastric cancer cells with high-level GA of *MET* are extraordinarily susceptible to the specific MET tyrosine kinase inhibitor PHA-665752 ([@bib28]). More recently, phase I and phase II clinical trials with MET inhibitors are ongoing for gastric cancer patients ([@bib6]; Liu *et al*, 2010), and among others, some inhibitors have been found to produce tumour regression in their clinical trials ([@bib18]; [@bib32]). However, the correlation between MET status and treatment response, and the optimal method to determine MET status in the tumours are undefined.

This study was designed to investigate the association between MET protein expression evaluated by immunohistochemistry (IHC) and gene copy number (GCN) evaluated by silver *in-situ* hybridisation (SISH) and to assess whether MET status determined by these two methods was associated with prognosis in a large series of consecutive gastric carcinoma cases.

Patients and methods
====================

Patients
--------

This retrospective study was conducted in a cohort of 438 gastric cancer patients that received a surgical resection of primary gastric carcinoma at Seoul National University Hospital, Seoul, Korea, in 2004. The only criteria used for patient selection included the availability of tumour tissue from primary gastric carcinoma (exclusion of mucosal cancer with the largest tumour diameter of ⩽1.5 cm) and survival data. Paraffin-embedded tumour specimens were used to construct a tissue microarray. Age, gender, tumour location, WHO ([@bib7]) and Lauren\'s classification, pTNM (pathologic Tumor-Node-Metastasis) stage (by seventh UICC/AJCC), and lymphatic invasion were evaluated by reviewing medical charts, pathological records, gross photographs, and glass slides. Median follow-up period of patients was 54 (range, 1--99) months. No patient received preoperative chemoradiotherapy, and patients with stage II, III, or IV disease received postoperative chemotherapy using fluorouracil (5FU)-based regimen (5FU alone, 5FU+mitomycin C, or 5FU+cisplatin). The study protocol was reviewed and approved by the Institutional Review Board of Seoul National University Hospital.

Tissue array methods
--------------------

Core tissue biopsies (2 mm in diameter) were taken from individual formalin-fixed, paraffin-embedded gastric carcinomas (donor blocks) and arranged in a new recipient paraffin block (tissue array block) using a trephine apparatus (Superbiochips Laboratories, Seoul, Korea). Because we have previously shown excellent agreement between the staining results of different intratumoural areas in gastric carcinomas ([@bib16]), a core was sampled from each case.

Immunohistochemistry
--------------------

Immunohistochemical staining was performed using an automatic immunostainer (BenchMark XT, Ventana Medical Systems, Tucson, AZ, USA), according to manufacturer\'s instructions. The primary antibody used was anti-total MET (SP44; rabbit monoclonal; prediluted; Ventana Medical Systems) antibody.

By using the DAKO HercepTest guideline (DAKO, Glostrup, Denmark), a semiquantitative approach was used to generate a score for each tissue core as follows: no membrane staining or membrane staining in \<10% of tumour cells (score 0), faint/barely perceptible partial membrane staining in \>10% of tumour cells (score 1+), weak-to-moderate staining of the entire membrane in \>10% of tumour cells (score 2+), and strong staining of the entire membrane in \>10% of tumour cells (score 3+). Scores of 0 and 1+ were considered as negative for MET overexpression, and scores of 2+ and 3+ were considered as positive. The IHC scoring was performed microscopically by two independent pathologists (WHK and HEL) unaware of the clinical details of individual patients. The case-by-case final consensus result was discussed and determined in a common session.

Dual-colour SISH
----------------

Automated SISH was performed on a Ventana BenchMark XT (Ventana Medical Systems). INFORM MET DNA Probe (Ventana Medical Systems) and INFORM Chromosome 7 Probe (Ventana Medical Systems) were visualised on the same slides, following manufacturer\'s protocols.

Signals were enumerated in at least 100 tumour nuclei per core, using a light microscope with objectives from × 20 to × 60. In some nuclei, clusters of dots representing many copies of *MET* gene were apparent. According to the interpretive guide for Ventana INFORM *HER2* DNA probe staining of breast carcinoma (Ventana Medical Systems), a small cluster of multiple signals was counted as 6 signals, and a large cluster as 12 signals.

By using the University of Colorado Cancer Center (UCCC) criteria for epidermal growth factor receptor gene ([@bib4]), the *MET* gene status was classified into six groups as follows: (i) disomy (⩽2 copies in ⩾90% of cells); (ii) low trisomy (⩽2 copies in ⩾40% of cells, 3 copies in 10--40% of cells, ⩾4 copies in \<10% of cells); (iii) high trisomy (⩽2 copies in ⩾40% of cells, 3 copies in ⩾40% of cells, ⩾4 copies in \<10% of cells); (iv) low polysomy (⩾4 copies in 10--40% of cells); (v) high polysomy (⩾4 copies in ⩾40% of cells); and (vi) GA (defined by the presence of tight *MET* gene clusters and a ratio of *MET* gene-to-chromosome of ⩾2 or ⩾15 copies of *MET* per cell in ⩾10% of analysed cells). High polysomy and GA were regarded as a positive SISH result, and others as a negative.

Laser-capture microdissection
-----------------------------

We collected tumour cells from tissue array slides. Briefly, 4-*μ*m paraffin-embedded tissue sections were deparaffinised with xylene. Rehydrated using graded ethanol series, stained with haematoxylin and eosin, rinsed in tap water, and finally immersed in 100% ethanol. After drying, areas of interest were identified. Tumour cells were selectively microdissected using a laser microdissection device (ION LMD, Jung Woo International, Co, Seoul, Korea). For DNA extraction, dissected cells were collected into 50 *μ*l of DNA extraction buffer, which was composed of 0.5% Tween-20, proteinase K (20 mg ml^−1^), and 50% Chelex-100 (Sigma Chemical Co, St Louis, MO, USA).

Quantitative real-time PCR
--------------------------

*MET* DNA amounts were determined using an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), and the data were analysed using SDS (Ver. 1.4) software (Applied Biosystems). Quantitative real-time PCR (qPCR) of *MET* was carried out using a Taqman Copy Number Assay (Assay ID, Hs02884964_cn; Applied Biosystems). *RNaseP* served as an endogenous control. A standard curve was generated for each gene with serial dilutions of standard DNA (100, 50, 25, 12.5, and 6.25 ng). The qPCR was done using 50 ng of template DNA from microdissected gastric carcinoma. Each analysis included a control without template DNA. After PCR amplification, a melting curve was generated for all PCR products to check PCR specificities. Normalised gene ratios were interpreted as follows: \<2=negative for GA and ⩾2.0=positive for GA. All results were normalised *vs* respective amounts of *RNaseP* DNA (Applied Biosystems).

Statistical analyses
--------------------

The *χ*^2^-test or Fisher\'s exact test (two-sided) was used to determine the nature of the correlations between protein expression or GCN and clinicopathologic parameters. The comparison of qPCR values between *MET*-amplified and MET-non-amplified groups was accomplished by Mann--Whitney *U*-test. The correlations between SISH and IHC or qPCR results were analysed using the Spearman rank method. Survival curves were plotted using the Kaplan--Meier product-limit method, and significance of differences between these curves was determined using the log-rank test. Multivariate survival analysis was performed using the Cox proportional hazards model. Results were considered significant when *P*-values were \<0.05. All statistical analyses were conducted using the PASW 19.0 statistical software program (IBM SPSS Statistics, Chicago, IL, USA).

Results
=======

MET protein expression
----------------------

MET protein expression was evaluated by IHC in 438 cases; 165 (37.7%), 169 (38.6%), 94 (21.5%), and 10 (2.3%) cases were scored as 0, 1+, 2+, and 3+, respectively ([Figure 1A--C](#fig1){ref-type="fig"}). A statistically significant difference in the MET expression was observed across the Lauren histological subtypes (*P*\<0.001; [Table 1](#tbl1){ref-type="table"}). Whereas IHC 3+ cases more frequently showed diffuse- or mixed-type (70%), IHC 2+ cases more frequently had intestinal-type cancers (67%). Among 181 intestinal-type cancers, 35% showed IHC 2+, which was significantly different from the expression observed in diffuse- or mixed-type cancers (12%). Furthermore, 63% (19 out of 30) of well-differentiated tubular adenocarcinoma cases were scored as 2+. Conversely, diffuse- or mixed-type cancers were mostly IHC negative (85%) in contrast to intestinal-type cancers (64%). However, the frequency of IHC 3+ was higher in diffuse- or mixed-type cancers than in intestinal-type cancers (2.7% *vs* 1.7%). Patients with IHC 3+ had significantly more frequent lymph-node metastases (*P*=0.008) and more advanced TNM stages (*P*=0.024) than the remaining cases. On the other hand, patients with IHC 2+ showed significantly less advanced TNM stages than those with IHC negative (*P*\<0.001).

*MET* GCN
---------

*MET* GCN was evaluated by SISH in 381 cases, and the SISH patterns are illustrated in [Figure 1D--F](#fig1){ref-type="fig"}. The average GCN per cell and the *MET*-to-chromosome 7 ratio for the SISH patterns are listed in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. In all, 133 (34.9%), 97 (25.5%), 77 (20.2%), 61 (16.0%), and 13 (3.4%) patients showed disomy, low trisomy, low polysomy, high polysomy, and GA, respectively. High trisomy was not detected. Among 13 patients showing *MET* GA, 3 had a low level of amplification (gene-to-chromosome ratio ranging between 2.1 and 3.0), and 10 had a high level of amplification (gene-to-chromosome ratio \>3), with the average per cell for the *MET* gene copies ranging from 5.6 to 41.6, and the ratio of gene-to-chromosome ranging from 2.1 to 19.3.

The distribution of the SISH patterns according to various clinicopathologic parameters is summarised in [Table 1](#tbl1){ref-type="table"}. Correlation between GA and Lauren type was not found; 6 of 13 cases with GA were intestinal-type and 7 were diffuse- or mixed-type cancers. However, high polysomy cases more frequently showed intestinal-type than diffuse- or mixed-type cancers. Among 163 intestinal-type cancers, 23% had high polysomy, which was significantly different from the gene status observed in diffuse- or mixed-type cancers (11%). The frequency of GA was similar between the two groups (3.7 and 3.2%). Patients with *MET* GA showed more frequent distant metastasis (*P*=0.031) and more advanced TNM stage (*P*=0.018) than those without *MET* GA. On the other hand, the TNM stage was not significantly different between high polysomy and SISH-negative cases.

*MET* GCN was also assessed by qPCR, which was performed on all 13 SISH-determined, *MET*-amplified gastric carcinoma tissues and on 13 non-amplified tissues. Calculated *MET*/*RNaseP* ratios being indicative of relative *MET* GCNs were higher in amplified cases than in non-amplified cases (median (interquartile range), 4.49 (1.94--13.29) *vs* 1.04 (0.76--1.44); *P*\<0.001) ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Also, scatter plot depicting the association between relative *MET* GCNs determined by qPCR and the GCNs by SISH indicated that there was a strong positive correlation (*r*=0.760; *P*\<0.001) ([Figure 2](#fig2){ref-type="fig"}).

Association between MET protein expression and GCN
--------------------------------------------------

The correlation between MET protein expression and GCN by SISH is presented in [Table 2](#tbl2){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}. There was a positive correlation between high protein expression and increased GCN (*r*=0.31; *P*\<0.001). Among the 283 patients with a negative MET expression, 249 patients (88.0%) had SISH negative, and the rest of the patients (12.0%) had high polysomy, and remarkably, none showed GA. In contrast, among the 88 patients with MET IHC 2+, 26 (29.5%) and 4 (4.5%) had high polysomy and GA, respectively. Also, all patients with IHC 3+ (*n*=10) had GA except 1, who had the average per cell for *MET* gene copies of 7.8 (range, 2--24), ratio of gene-to-chromosome of 1.56, and tumour cells ⩾15 copies of *MET* per cell in 8% of analysed cells, and therefore, the case was categorised as high polysomy according to the UCCC criteria.

Patients with MET SISH negative tended to have low IHC scores, whereas the IHC score increased when SISH abnormalities became more severe ([Figure 3](#fig3){ref-type="fig"}). Specifically, in the comparison of total cases, the higher was the *MET* GCN, the lower was the frequency of IHC 0 and the higher was that of IHC 2+ and IHC 3+. That of IHC 1+ was similar among the groups of SISH pattern. Notably, among 13 cases of GA, 4 (30.8%) and 9 (69.2%) showed IHC 2+ and IHC 3+, respectively, whereas none had IHC 0 or IHC 1+ ([Figure 3A](#fig3){ref-type="fig"}). These results suggested that a low number of *MET* gene copies per cell, including disomy and trisomy, had not influenced the level of protein expression, whereas a high number of gene copies, both as high polysomy and as GA, had an impact on the protein level.

When the association between protein expression and gene levels was also investigated according to the Lauren histologic subtype, it was found that the high number of gene copies per cell was closely associated with high protein expression independent of histology (*r*=0.35, *P*\<0.001 in intestinal-type; *r*=0.19, *P*=0.004 in diffuse- or mixed-type cancers). Interestingly, in the GA group of intestinal-type cancers, the frequency of IHC 2+ was higher than that of IHC 3+ (66.7% *vs* 33.3%). In contrast, in the cases of diffuse- or mixed-type cancers, all cases showing GA showed IHC 3+ and vice versa ([Figure 3B and C](#fig3){ref-type="fig"}).

Prognostic implications of MET protein expression and GCN
---------------------------------------------------------

Kaplan--Meier survival curves for patients in the different categories of MET protein expression are shown in [Figure 4](#fig4){ref-type="fig"}. Whereas the group of IHC 3+ had a shorter overall survival (OS) time than that of IHC negative, the group of IHC 2+ had a longer OS time, which was independent of the Lauren histologic subtype. In the subgroup analyses of disease stage, there was no difference in OS among the three IHC score groups in stage I--II. In stage III--IV, survival differences were found among the IHC score groups, although they did not reach statistical significances. In multivariate analyses, MET protein expression level was not a significant independent prognostic factor (data not shown).

Kaplan--Meier survival curves for patients in different categories of *MET* gene level are shown in [Figure 5](#fig5){ref-type="fig"}. Survival, as a function of *MET* GCN, was found to decrease with increasing GCN. However, the group of high polysomy tended to have a longer OS time than that of low polysomy although it was not a statistically significant difference. Also, when the patients were divided into SISH negative, high polysomy, and GA, the patient OS time tended to decrease with increasing copy number. In the subgroup analysis of diffuse- or mixed-subtype cancers, the trend was more profound. On the other hand, in the subgroup of intestinal subtype, the high polysomy group tended to have a longer survival time than the SISH-negative group, although it was not statistically significant. Whereas this association was further confirmed when survival analysis was limited to patients with stage III and IV disease, it was not found when the analysis was limited to those with stage I and II disease. The hazard ratio was calculated for the MET SISH result as shown in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}, after adjusting for the most commonly used clinical prognostic markers including tumour invasion, lymph-node metastasis, distant metastasis, residual tumour, and Lauren histologic subtypes, which were all found to have prognostic significance by univariate analyses. *MET* GA was associated with a significantly increased hazard ratio of 2.27 (95% CI, 1.05--4.93) compared with patients with tumours not having GA independent of other classical prognostic factors.

Associations between MET protein expression or gene status and disease-free survival (DFS) were shown in [Supplementary Figure S2 and S3](#sup1){ref-type="supplementary-material"}, respectively. High protein expression and GA were related to the shorter DFS time. In addition, IHC 3+ and GA were found to be independent negative prognostic factors for DFS in multivariate analyses ([Supplementary Tables S3 and S4](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The need for accurate detection of the MET alteration has now become even more important, because therapeutic decisions for patients as well as determining patient prognosis are possibly dependent on this information. In the present study, we performed direct comparison of *MET* GCN per cell detected by SISH with MET protein expression evaluated by IHC and have shown that there was a significant correlation between increased GCN and the high level of protein expression. Furthermore, we demonstrated that strong protein expression (IHC 3+) or GA of *MET* was significantly associated with patient poor survival in a large, unselected, consecutively accrued gastric cancer cohort.

*In-situ*-based technologies such as IHC and SISH/fluorescence ISH (FISH) are standardised methods for detecting genetic alteration in clinical practice, and data on the correlation between these methods would be critical to determine the guideline for MET evaluation of cancer patients. However, to date, only a few small studies have compared IHC with FISH ([@bib5]; [@bib14]). In this study, we evaluated MET IHC and SISH concurrently in a large archival gastric cancer cohort. Direct comparison of the results revealed the positive correlation between high protein expression and increased GCN. Notably, all cases with GA (*n*=13) showed MET protein overexpression (IHC 2+ in 4 and IHC 3+ in 9), which means that none of the IHC-negative cases had GA. Furthermore, all cases with IHC 3+ had GA except 1 showing high polysomy. Indeed, tumour cells in that case possessed the average *MET* gene copy of 7.8, and therefore, this case could be categorised as GA when we adopted the ASCO/CAP guideline (2007) for HER2 assessment ([@bib31]). Also, in the cases of diffuse- or mixed-type cancers, *MET*-amplified tumours exactly corresponded with IHC 3+ tumours. These findings suggest that strong expression of the MET protein (IHC 3+) well represents GA, and thus, MET IHC can be an alternative method to replace FISH or SISH for patient selection for anti-MET therapy if GA is a major determinant of drug responsiveness. However, because a part of *MET*-amplified cases presented IHC 2+, SISH or FISH method would be necessary for the accurate assessment of GA status in the cases of IHC 2+.

The positive correlation between increasing levels of MET protein expression and increased GCN indicates that the additive effect of gene copies such as polysomy of chromosome 7 and GA is an important mechanism of MET protein overexpression. However, a part of gastric carcinomas showed disomy while overexpressing MET protein, and on the contrary, a fraction of tumours with high polysomy did not show MET protein overexpression, suggesting that MET protein expression might also be controlled by mechanisms other than gene copy increase. One such mechanism is the transcriptional mechanism; earlier studies have reported that other oncogenes such as activated RAS can induce MET overexpression through transcriptional mechanism ([@bib13]; [@bib8]).

This is the first study of *MET* GCN using SISH, a newly developed method. This assay has many advantages over FISH ([@bib24]); and thus, HER2 SISH is widely used in current clinical practice. Because there were, however, no validation data on MET GCNs by SISH, we attempted to verify the SISH results by comparing with qPCR data. In this study, it was found that *MET* GCNs by SISH and qPCR were strongly correlated, although 3 of 13 SISH-determined, *MET*-amplified cases showed the relative GCN of \<2.0 by qPCR. We guess that these discordant cases are due to intratumoural heterogeneity of *MET* GA. Indeed, some of the amplified cases showed the marked intratumoural heterogeneity by SISH within even a 2-mm-sized tissue array core. These results indicate that *MET* SISH is an accurate and reliable method to examine the *MET* GCN, although further study such as comparison with FISH is required.

In spite of the great interest on MET, only a few studies have investigated the clinical implications of MET protein expression ([@bib22]; [@bib12]; [@bib1]; [@bib14]; [@bib33]; [@bib29]) or copy number gain ([@bib22]; [@bib10]; [@bib17]; [@bib18]). In this study, we assessed the impact of MET status on clinical outcome, and particularly performed survival analyses according to GCN examined by SISH in a large gastric cancer cohort. Whereas strong expression of MET (IHC 3+) was associated with diffuse- or mixed-type cancers, advanced disease stage, and poor OS, moderate expression (IHC 2+) was correlated with intestinal-type cancers, less advanced disease stage, and favourable prognosis. *MET* GA was not associated with the Lauren histologic subtype but tended to correlate with advanced disease stage. Also, gastric cancer patients with *MET* GA had a shorter survival time irrespective of other classical prognostic factors, indicating that *MET* GA is an independent negative prognostic factor in gastric cancer.

Subgroup analyses according to the disease stage elucidated that *MET* GA did not have an impact on prognosis in early TNM stage (stage I or II), unlike in advanced TNM stage (stage III or IV). All four tumours of early TNM stage showed both intestinal type and IHC 2+, and three had a low level of *MET* GA. On the other hand, seven out of nine tumours of advanced TNM stage were diffuse or mixed type, and all showed both IHC 3+ and a high level of GA. These findings suggest that there was a significant association between diffuse- or mixed-type cancers and a high level of GA, and that only a high level, but not a low level, of *MET* GA exerts a respectable influence on disease progression and patient survival. Also, the findings indicate that *MET* gene alteration can be acquired during the early phase of development of gastric cancer, especially intestinal-type cancer, and exaggerated during cancer progression.

An interesting finding is the different effect of high polysomy of chromosome 7 on patient survival according to the Lauren histologic subtype. Whereas intestinal-type cancers with high polysomy tended to show better prognosis than those with either SISH negative or GA, diffuse- or mixed-type cancers with high polysomy showed better prognosis than those with GA, but worse than those with SISH negative. In addition, high polysomy was much more common in intestinal-type cancers than in diffuse- or mixed-type cancers. Future studies need to explain these findings.

In this study, MET protein overexpression was found in 23.8%, with a score of 2+ in 21.5% and a score of 3+ in 2.3%. Previous studies describe much variable frequencies of MET protein overexpression (24--71%) in gastric cancer ([@bib22]; [@bib12]; [@bib1]; [@bib14]; [@bib33]; [@bib29]). The lack of standardisation in staining procedures and guidelines for interpretation of the MET IHC assessment as well as the difference in antibodies used may be the major reasons for the largely variable results across studies. Also, different sampling size and cohort characteristics might contribute to explain differences in the results. In this study, we immunostained using the Ventana monoclonal antibody (clone: SP44) and interpreted according to the DAKO HercepTest guideline for gastric cancer. The impact on the outcome by using different antibodies and scoring systems for immunohistochemical staining assessment of MET should be addressed in future comparative investigations.

Earlier results on *MET* GA frequency of gastric cancer were also much variable (0--23%), and most of them are higher than the frequency of the present study (3.4%). The reason seems to be mainly due to the difference in methodology (ISH, Southern blot, or qPCR). Indeed, whereas studies using Southern blot analyses or qPCR reported the quite high frequency of 9--23% ([@bib15]; [@bib30]; [@bib23]; [@bib22]; [@bib25]; [@bib10]; [@bib17]), those using FISH described the frequency of none ([@bib14]), 2.4% ([@bib18]), and 3.9% ([@bib11]) of gastric cancer, which is similar to that of our study. Southern blot analysis and qPCR have the high chance of overestimating the incidence of *MET* GA because it cannot discriminate polysomy from GA. Nowadays, FISH or SISH using ISH technology has replaced Southern blot analysis or qPCR because of more accurate information on the GCN of tumour cells in tissue sections.

This study did not attempt to reveal the association of *MET* GCN or protein expression with the responsiveness of MET inhibitors. However, our findings on the correlation between MET protein expression and GCN and their clinical implications would be an important basis in future studies about patient selection for anti-MET therapy. Clinical and pathologic parameters might have a role in the identification of the group of patients most likely to benefit from anti-MET therapy, and future studies need to evaluate the direct correlation between the parameters and the drug responsiveness to determine the optimal target population.

In conclusion, we investigated MET GCN and protein expression using SISH and IHC, respectively, in a large series of gastric cancer. The significant correlation between increased GCN and high protein expression of MET and the approximate correspondence of IHC 3+ and GA suggest that MET IHC could be a primary screening test for patient selection for anti-MET therapy if GA is a major determinant of drug responsiveness. In addition, our finding that GA and strong expression of MET were negative prognostic factors indicates that anti-MET therapy is a very promising modality in the field of adjuvant treatment for gastric cancer patients.
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![Representative microphotographs of MET IHC (**A**--**C**) and SISH (**D**--**F**). Cases of no membranous staining (IHC 0; **A**), weak-to-moderate staining of the entire membrane (IHC 2+ **B**), and strong staining of the entire membrane (IHC 3+ **C**) by IHC, and cases of disomy (**D**), high polysomy (**E**), and GA (**F**) by SISH are shown.](bjc2012237f1){#fig1}

![Scatter plot depicting the association between relative *MET* gene copy numbers determined by qPCR and SISH. There was a strong positive correlation between the *MET*/*RNaseP* ratio by qPCR and the *MET*/chromosome 7 ratio by SISH (*r*=0.760; *P*\<0.001).](bjc2012237f2){#fig2}

![MET protein expression levels plotted according to the SISH patterns in total cases (**A**; *n*=381), intestinal-type cancers (**B**; *n*=163), and diffuse- or mixed-type cancers (**C**; *n*=218). The IHC score increased when SISH abnormalities became more severe irrespective of the Lauren histologic subtype. Specifically, the higher was the *MET* gene copy number, the lower was the frequency of IHC 0 and the higher was that of IHC 2+ and IHC 3+. That of IHC 1+ was similar among the groups of SISH pattern. Notably, among 13 cases of gene amplification, 4 (30.8%) and 9 (69.2%) showed IHC 2+ and IHC 3+, respectively, whereas none had IHC 0 or IHC 1+. In the gene amplification group of intestinal-type cancers, the frequency of IHC 2+ was higher than that of IHC 3+ (66.7% *vs* 33.3%). In contrast, in cases of diffuse- or mixed-type cancers, cases showing gene amplification exactly corresponded with those with IHC 3+. Abbreviations: DS=disomy; GA, gene amplification; HP=high polysomy; LP=low polysomy; LT=low trisomy.](bjc2012237f3){#fig3}

![Kaplan--Meier curves for overall survival according to the level of MET protein expression. Whereas the group of IHC 3+ had a shorter survival time than that of IHC negative, the group of IHC 2+ had a longer survival time (**A** and **B**), which was independent of the Lauren histologic subtype (**C** and **D**). In the subgroup analyses of disease stage, there was no difference in survival among the three IHC score groups in stages I--II (**E**). In stages III--IV, survival differences were found among the IHC score groups, although they did not reach statistical significances (**F**).](bjc2012237f4){#fig4}

![Kaplan--Meier curves for overall survival according to the level of *MET* gene copy number. Overall survival times were found to decrease with increasing gene copy number (**A** and **B**), but the group of high polysomy tended to have a longer survival time than that of low polysomy although it was not a statistically significant difference. In the subgroup analysis of intestinal-type cancers, the high polysomy group tended to have a longer survival time than the SISH-negative group, although it was not statistically significant (**C**). On the other hand, in the subgroup of diffuse- or mixed-type cancers, survival times became significantly shorter as the *MET* gene copy number increased (**D**). In the subgroup analysis of stage I and II disease, survival times were not different according to the level of gene copy number (**E**). However, when survival analysis was limited to patients with stage III and IV disease, survival times became significantly shorter as the *MET* gene copy number increased (**F**).](bjc2012237f5){#fig5}

###### Clinicopathologic characteristics of gastric carcinoma patients according to MET status

                                              **MET IHC**                                                 ***MET*** **SISH**                                                                                                                                                    
  ----------------------------- --------------------------------------- --------------------------------- -------------------------------- ------------------- --------------------------------------------- --------------------------------- -------------------------------- -------------------
                                             **Negative**                         **Positive**                                                **Negative**                     **Positive**                                                                                     
                                 **0 or 1+ (*****n*****=334 (76.3%))**   **2+ (*****n*****=94 (21.5%))**  **3+ (*****n*****=10 (2.3%))**    ***P-*****value**   **DS, LT, or LP (*****n*****=307 (80.6%))**   **HP (*****n*****=61 (16.0%))**  **GA (*****n*****=13 (3.4%))**   ***P-*****value**
  Age (mean±s.d., years)                       56.8±12.8                            59.3±12.1             66.5±11.3                               0.018                          57.4±12.6                               58.8±13.3             65.5±12.5                        0.114
                                                                                                                                                                                                                                                                                 
  *Gender, n (%)*                                0.193                                                                                                                             0.015                                                                                        
   Male                                       235 (70.4)                            75 (79.8)             7 (70.0)                                                              213 (69.4)                               53 (86.9)             8 (61.5)                          
   Female                                      99 (29.6)                            19 (20.2)             3 (30.0)                                                               94 (30.6)                               8 (13.1)              5 (38.5)                          
                                                                                                                                                                                                                                                                                 
  *Lauren, n (%)*                               \<0.001                                                                                                                            0.008                                                                                        
   Intestinal                                 115 (34.4)                            63 (67.0)             3 (30.0)                                                              120 (39.1)                               37 (60.7)             6 (46.2)                          
   Diffuse of mixed                           219 (65.6)                            31 (33.0)             7 (70.0)                                                              187 (60.9)                               24 (39.3)             7 (53.8)                          
                                                                                                                                                                                                                                                                                 
  *Tumour invasion, n (%)*                      \<0.001                                                                                                                            0.323                                                                                        
   EGC                                         72 (21.9)                            45 (47.9)             0 (0)                                                                  95 (30.9)                               15 (24.6)             2 (15.4)                          
   AGC                                        261 (78.1)                            49 (52.1)             10 (100.0)                                                            212 (69.1)                               46 (75.4)             11 (84.6)                         
                                                                                                                                                                                                                                                                                 
  *LN metastasis, n (%)*                         0.001                                                                                                                             0.142                                                                                        
   No                                         127 (38.0)                            53 (56.4)             1 (10.0)                                                              142 (46.3)                               20 (32.8)             5 (38.5)                          
   Yes                                        207 (62.0)                            41 (43.6)             9 (90.0)                                                              165 (53.7)                               41 (67.2)             6 (61.5)                          
                                                                                                                                                                                                                                                                                 
  *Distant metastasis, n (%)*                    0.003                                                                                                                             0.060                                                                                        
   No                                         290 (86.8)                            89 (94.7)             6 (60.0)                                                              276 (89.9)                               55 (90.2)             9 (69.2)                          
   Yes                                         44 (13.2)                             5 (5.3)              4 (40.0)                                                               31 (10.1)                                6 (9.8)              4 (30.8)                          
                                                                                                                                                                                                                                                                                 
  *TNM* *stage, n (%)*                          \<0.001                                                                                                                            0.193                                                                                        
   I                                           98 (29.3)                            48 (51.1)             0 (0)                                                                 116 (37.8)                               19 (31.1)             3 (23.1)                          
   II                                          79 (23.7)                            21 (22.3)             1 (10.0)                                                               67 (21.8)                               17 (27.9)             1 (7.7)                           
   III                                        113 (33.8)                            20 (21.3)             5 (50.0)                                                               93 (30.3)                               19 (31.1)             5 (38.5)                          
   IV                                          44 (13.2)                             5 (5.3)              4 (40.0)                                                               31 (10.1)                                6 (9.8)              4 (30.8)                          

Abbreviations: AGC=advanced gastric carcinoma; DS=disomy; EGC=early gastric carcinoma; GA=gene amplification; HP=high polysomy; IHC=immunohistochemistry; LN=lymph node; LP=low polysomy; LT=low trisomy; s.d.=standard deviation; SISH=silver *in-situ* hybridisation; TNM=Tumor-Node-Metastasis. *χ*^2^ or Fisher\'s exact test was used in each analysis except for the analysis of age factor (analysis of variance).

###### Associations between MET protein expression and *MET* gene copy number

                     ***MET*** **SISH patterns**                                                                               
  ----------------- ----------------------------- ----------------- ------------------ ------------------- ------------------- -----------
                             **Disomy**            **Low trisomy**   **Low polysomy**   **High polysomy**   **Amplification**   **Total**
  *MET IHC*                                                                                                                    
   0, *n* (%)                 56 (43.1)               39 (30.0)         21 (16.2)           14 (10.8)             0 (0)         130 (100)
   1, *n* (%)                 60 (39.2)               38 (24.8)         35 (22.9)           20 (13.1)             0 (0)         153 (100)
   2, *n* (%)                 17 (19.3)               20 (22.7)         21 (23.9)           26 (29.5)            4 (4.5)        88 (100)
   3, *n* (%)                   0 (0)                   0 (0)             0 (0)             1 (10.0)            9 (90.0)        10 (100)
   Total, *n* (%)            133 (34.9)               97 (25.5)         77 (20.2)           61 (16.0)           13 (3.4)        381 (100)

Abbreviations: IHC=immunohistochemistry; SISH=silver *in-situ* hybridisation.
